These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2351926)

  • 41. Low bone mineral density in adult patients with moderate to severe atopic dermatitis.
    Haeck IM; Hamdy NA; Timmer-de Mik L; Lentjes EG; Verhaar HJ; Knol MJ; de Bruin-Weller MS; Bruijnzeel-Koomen CA
    Br J Dermatol; 2009 Dec; 161(6):1248-54. PubMed ID: 19673879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.
    Weyand CM; Fulbright JW; Hunder GG; Evans JM; Goronzy JJ
    Arthritis Rheum; 2000 May; 43(5):1041-8. PubMed ID: 10817557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corticosteroids for rheumatic disease. 2. Effects on disease states, effects on bone.
    Jamieson T
    Postgrad Med; 1986 Apr; 79(5):247-8, 250. PubMed ID: 3485794
    [No Abstract]   [Full Text] [Related]  

  • 44. Audiovestibular manifestations in giant cell arteritis: a prospective study.
    Amor-Dorado JC; Llorca J; Garcia-Porrua C; Costa C; Perez-Fernandez N; Gonzalez-Gay MA
    Medicine (Baltimore); 2003 Jan; 82(1):13-26. PubMed ID: 12544707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.
    Mulder H; Struys A
    Br J Rheumatol; 1994 Apr; 33(4):348-50. PubMed ID: 8156307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of inhaled corticosteroids on bone mineral density measured by quantitative ultrasonography in an older population.
    Sarwar G; Bisquera A; Peel R; Hancock S; Grainge C; Attia J
    Clin Respir J; 2018 Feb; 12(2):659-665. PubMed ID: 27805313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives.
    Ferraccioli GF; Di Poi E; Damato R
    Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S58-60. PubMed ID: 10948766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis.
    Karahaliou M; Vaiopoulos G; Papaspyrou S; Kanakis MA; Revenas K; Sfikakis PP
    Arthritis Res Ther; 2006; 8(4):R116. PubMed ID: 16859533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.
    Richy F; Ethgen O; Bruyere O; Reginster JY
    Osteoporos Int; 2004 Apr; 15(4):301-10. PubMed ID: 14740153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study.
    Mohammad AJ; Englund M; Turesson C; Tomasson G; Merkel PA
    J Rheumatol; 2017 Jan; 44(1):84-90. PubMed ID: 27803140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymyalgia rheumatica and giant cell arteritis.
    Subrahmanyan P; Dasgupta B
    Br J Hosp Med (Lond); 2006 May; 67(5):240-3. PubMed ID: 16729627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteoporosis in steroid-dependent asthma.
    Villareal MS; Klaustermeyer WB; Hahn TJ; Gordon EH
    Ann Allergy Asthma Immunol; 1996 Apr; 76(4):369-72. PubMed ID: 8612121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Giant cell arteritis after the age of 75].
    Chevalet P; Masseau-Imbert A; Durand-Fix MH; Agard C; Brisseau JM; Rodat O; Barrier JH
    Ann Med Interne (Paris); 2002 Oct; 153(6):373-7. PubMed ID: 12486385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
    Miyabe C; Miyabe Y; Strle K; Kim ND; Stone JH; Luster AD; Unizony S
    Ann Rheum Dis; 2017 May; 76(5):898-905. PubMed ID: 27927642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study.
    Pugnet G; Sailler L; Bourrel R; Montastruc JL; Lapeyre-Mestre M
    J Rheumatol; 2015 Feb; 42(2):316-22. PubMed ID: 25512477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.
    Gonzalez-Gay MA; Garcia-Porrua C; Miranda-Filloy JA; Martin J
    Drugs Aging; 2006; 23(8):627-49. PubMed ID: 16964987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose corticosteroid exposure and osteoporosis intervention in adults.
    Che M; Ettinger B; Nguyen MT; Pressman AR; Johnston J
    Ann Allergy Asthma Immunol; 2006 Oct; 97(4):497-501. PubMed ID: 17069105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.
    van der Geest KS; Abdulahad WH; Chalan P; Rutgers A; Horst G; Huitema MG; Roffel MP; Roozendaal C; Kluin PM; Bos NA; Boots AM; Brouwer E
    Arthritis Rheumatol; 2014 Jul; 66(7):1927-38. PubMed ID: 24623536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term corticosteroid treatment in giant cell arteritis.
    Andersson R; Malmvall BE; Bengtsson BA
    Acta Med Scand; 1986; 220(5):465-9. PubMed ID: 3812030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Simple Horton's syndrome: modalities of treatment].
    Agard C; Barrier JH
    Presse Med; 2004 Jan; 33(1):41-50. PubMed ID: 15026724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.